c-MET (V1092I)

MET · Variant type: point · HGVS: p.V1092I

Drug response on this variant

#	Drug	Inhibition on variant	Residual	KISS
1	Cabozantinib	98.7%	1.3%	92.73
2	Tepotinib	92.8%	7.2%	99.75
3	Deucravacitinib	91.0%	9.0%	98.99
4	Capmatinib	90.2%	9.8%	99.75
5	Crizotinib	88.7%	11.3%	91.39
6	Gilteritinib	84.0%	16.0%	88.97
7	Tivozanib	82.3%	17.7%	92.42
8	Erdafitinib	61.9%	38.1%	95.71
9	Fostamatinib	60.0%	40.0%	96.74
10	Defactinib	50.9%	49.1%	92.68
11	Vemurafenib	47.7%	52.3%	96.49
12	Afatinib	43.3%	56.7%	98.50
13	Sunitinib	43.2%	56.8%	91.73
14	Imatinib	41.9%	58.1%	99.00
15	Neratinib	40.5%	59.5%	93.18
16	Canertinib	38.6%	61.4%	96.49
17	Lenvatinib	36.0%	64.0%	97.74
18	Selpercatinib	35.0%	65.0%	96.72
19	Repotrectinib	32.9%	67.1%	84.21
20	Dacomitinib	29.5%	70.5%	97.99
21	Pacritinib	23.2%	76.8%	88.64
22	Entrectinib	23.2%	76.8%	93.69
23	Axitinib	23.2%	76.8%	93.23
24	Fedratinib	22.0%	78.0%	96.21
25	Pexidartinib	20.8%	79.2%	99.49

Positive Δ means the drug hits the variant harder than wild-type (mutation-selective); negative Δ means it loses potency (resistance).

Drug	Variant inh	WT inh	Δ (variant − WT)
Cabozantinib	98.7%	—	—
Tepotinib	92.8%	—	—
Deucravacitinib	91.0%	—	—
Capmatinib	90.2%	—	—
Crizotinib	88.7%	—	—
Gilteritinib	84.0%	—	—
Tivozanib	82.3%	—	—
Erdafitinib	61.9%	—	—
Fostamatinib	60.0%	—	—
Defactinib	50.9%	—	—
Vemurafenib	47.7%	—	—
Afatinib	43.3%	—	—
Sunitinib	43.2%	—	—
Imatinib	41.9%	—	—
Neratinib	40.5%	—	—
Canertinib	38.6%	—	—
Lenvatinib	36.0%	—	—
Selpercatinib	35.0%	—	—
Repotrectinib	32.9%	—	—
Dacomitinib	29.5%	—	—
Pacritinib	23.2%	—	—
Entrectinib	23.2%	—	—
Axitinib	23.2%	—	—
Fedratinib	22.0%	—	—
Pexidartinib	20.8%	—	—

Loading…

Served from saifudeen2026@1.0.0 · API 0.1.0 · 14.3ms